The selected companies will be supported by Bayer's G4ADigital Health Partnerships program to drive forward innovative solutions for patients.
For the next three months, these 10 companies will iterate on their business models and accelerate their companies through access to capital and mentorship.
Selected companies are developing innovations in gene therapy, chronic condition management, and social isolation of the elderly.
A deal slump that started in Q3 of last year, has now increased for the second quarter in a row.
Teams from each company will spend three months in Los Angeles working closely with Cedars-Sinai mentors, including doctors, researchers and administrators.
These companies span direct-to-consumer goods, diagnostic devices, and remote patient monitoring in payer, provider and employer spaces.
The market is seemingly slowing down, but both companies see other reasons to be optimistic about digital health investment.
The cohort was selected by a pool of institutions, providers, and payors looking to form partnerships and solve challenges with digital health startups.
Put into dollars, that's $8B raised in 556 deals during the first 9 months of 2018, compared to $5.5B in 586 deals during the same period last year.
The program is designed to rapidly pilot technologies of NYC-based startups to advance healthcare, create jobs and strengthen City's health tech sector.